Navigation Links
ULURU Inc. Presents Results of First Randomized Clinical Trial for Altrazeal(TM) at the Symposium on Advanced Wound Care (SAWC) Fall Meeting in Washington D.C.
Date:9/16/2009

ADDISON, Texas, Sept. 16 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today the presentation of results from the first completed randomized clinical trial for Altrazeal at the SAWC Fall symposium in Washington D.C. September 16-18. The recently completed clinical study compared healing, pain and comfort of skin graft donor sites treated with either Altrazeal(TM) or with a leading commercial sodium carboxymethylcellulose-silver ("CMC-Ag") dressing.

Major results from the study indicated that there was a significant difference in patient's pain scores, all favoring Altrazeal with lower pain scores at each time point (p<0.0001). When asked about the comfort of the wound dressing at the edges, these subjects found Altrazeal to be more comfortable (p<0.001) and less painful when the dressing came in contact with clothes or bedding (p<0.001). The study endpoints validated the hypothesis for time to healing for both dressings in this particular type of acute surgical wound.

The study was a single-center, prospective randomized trial in which each patient served as his/her own control. Each patient had at least two split-thickness donor sites of which one was dressed with Altrazeal(TM) and the other one with the CMC-Ag dressing.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "We are extremely delighted with the results of this clinical trial. Skin graft donor sites are an acute wound that typically heals without any complications, so we expected to show little difference in healing. Nonetheless, these type of surgical wounds are nearly always extremely painful to the patient and to show statistical significance in pain and patient comfort versus a well recognized leading global brand confirms the attributes of Altrazeal(TM) and its promising future."

In addition to the randomized clinical t
'/>"/>

SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ULURU Inc. Reports Second Quarter 2009 Financial Results
2. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update
3. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
4. ULURU Inc. Announces Status of York Note Receivable
5. ULURU Inc. Reports First Quarter 2009 Financial Results
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2009 and to Provide a Business Update
7. ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
8. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
9. ULURU Inc. (ULURU) Dealing Disclosure Requirements
10. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
11. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...suffering from women,s hair loss for almost ten ye...e,s sharing her progress and the secret behind her... release of her video diaries which include a dire...eatment. , (PRWeb UK) Nov...sanett Siklosi has released the video diaries that...
(Date:11/23/2009)...ndividualsintheRecommendedPriorityGroups ,, HAR...partmentofHealthannouncedtodaytheywillconductthree...CentersinDelaware,Lancaster,andLehighcountiesonTue...beadministeredforfreetoindividualsintherecommended...ne.Thedepartmentasksthatonlyindividualsinthefollow...
(Date:11/23/2009)...ofessionals enjoy a pay raise for a job well done....ealth care performance may actually backfire. ,...mance ratings for 25 medical groups across Califor... a statewide pay-for-performance program in 2004 ...tivity. , Reporting in the December edition o...
(Date:11/23/2009)... to head the agency, said lives could be at risk ,...he fallout from last week,s controversial recommen...gram testing for breast cancer continues, with a f...th advising women to ignore the guidelines. , "...equivocally this will increase the number of women...
(Date:11/23/2009)...inance"reform"isamoraloutrage ,, WASHINGTON,N...atsmovedforwardtobeginthedebateontheirhealthcare"r...stronggrassrootssenioradvocacygroup,iscallingonall...massivecutstoMedicare.RetireSafePresidentThairPhil...iketaxes,abortion,andimmigration,whilethesimple,un...
Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2
...AN CITY, Shandong, China, May 22 /Xinhua-PRNewswir... Bulletin Board: CBPO) (,CBP, or ,the,Company,), o...anies in the,People,s Republic of China (,PRC,), t...on to a more favorable,location with a wider cover...
...TVALE, N.J., May 22 Menstrual migraine, a conditi...w supplement to OBG,Management. "Integrating menst...describes the relationship between hormone fluctua...rual,migraine are also discussed., "Integrating m...
...io of ,good, to ,bad, cholesterol determined chanc... , , THURSDAY, May 22 (HealthDay News) -- ...which women are at risk for heart problems while ...ttacks while taking hormone therapy, while women w...
...vate equity backed holding company enters into agr...hare in MedQuist, MOUNT LAUREL, N.J., May 22 Med...t earlier today Koninklijke Philips,Electronics N....st to CBaySystems Holdings Ltd., a publicly traded...
...HINGTON, May 21 The American Lung,Association has...icit the,public,s help in exposing the most egregi...d teens in communities nationwide. These photos,wi...on encourages all concerned individuals to,expose ...
...R also Reports 1st quarter profit, enhanced operat...nts, LOS ANGELES, May 21 InstaCare Corp., (OTC,B...home testing diagnostics,for the chronically ill, ...rst quarter period-ended March 31, 2008. Recent,hi...
Other Medicine News:Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 2Health News:China Biologic Products Announces Approval for the Relocation of Fang Cheng Plasma Collection Station and for the Procurement of Excess Clinical Plasma 3Health News:CME Publication Tackles a Problem that is a Real Headache for Women 2Health News:Cholesterol Test Spots When HRT Raises Heart Risks 2Health News:Cholesterol Test Spots When HRT Raises Heart Risks 3Health News:MedQuist to Get New Majority Stakeholder 2Health News:MedQuist to Get New Majority Stakeholder 3Health News:MedQuist to Get New Majority Stakeholder 4Health News:American Lung Association Launches Online Photo Campaign to Expose Big Tobacco in Communities Nationwide 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5
(Date:11/23/2009)..., BIRMINGHAM,Ala.andNOIDA,India,Nov.23/PRNews...fAlabamaatBirmingham(UAB),andSouthernResearchInsti...ragingtheircollectiveinnovationandenablingtechnolo...iousDiseases.ItisauniqueU.S.-Indiaarbitragedandlev...faffordabletherapiesforpatientsworldwide.AMemorand...
(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRese...M): Feraheme report,thesecondinamulti-phasesyndi...snewIVironproduct,Feraheme,throughthefirstsixmonth...quantitativeinformationfrom50uniqueNephrologistsan...ssesstrialanduseofFeraheme,obstaclestouse,reasonst...
(Date:11/23/2009)..., LASVEGAS,Nov.23/PRNewswire-FirstCall/--Cord...calcordbloodstemcellpreservationcompany( http://ww...avingpotentialofstemcells,abiologicalinsurancepoli...dtodaythatanupdatedprogressinterviewwithCEOandco-f...ireinterviewisat: http://blip.tv/file/2875811 . ,...
Breaking Medicine Technology:Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2HealthPlus Named One of Americas Best Health Insurance Plans Again 61201 1HealthPlus Named One of Americas Best Health Insurance Plans Again 61201 2Employment Policies Institute Launches 2410 Million Campaign Urging the Public to Rethink Health Care Reform 61198 1Employment Policies Institute Launches 2410 Million Campaign Urging the Public to Rethink Health Care Reform 61198 2Interdisciplinary research team developing novel drug detection technology 14802 1Interdisciplinary research team developing novel drug detection technology 14802 2Interdisciplinary research team developing novel drug detection technology 14802 3Interdisciplinary research team developing novel drug detection technology 14802 4
.... 13 Chroma Therapeutics Limited,one of the UK,s ... today,positive data from a Phase I study with its...2797 in the treatment of patients with acute myelo... and multiple myeloma (MM),who have failed on, or ...ata from the study, which was presented by a key s...
...Dec. 12 Nuvelo, Inc.,(Nasdaq: NUVO ) today annou...f-of-concept trial of alfimeprase for the treatmen... granted fast track designation by the U.S. Food,a...is indication. Fast,track designation, which was m...otentially facilitate expedited review of a Biolog...
Other Medicine Technology:Chroma Announces Positive Phase I Efficacy Data for Novel Cancer Therapy CHR-2797 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 2Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 3Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke 4
Budde Halo Brain Retractor
Love-Adson Periosteal Elevator
Hoen Periosteal Elevators
Cushing Little Joker Periosteal Elevators
Medicine Products: